Pressure BioSciences Gives Guidance for Strong Q4 2022 Sales Followed by Rapid Revenue Growth from Multiple Large Industries in 2023 – Yahoo Finance

Foundations Built and Momentum Achieved in 2022 Expected to Drive Company to Significant Revenue Levels, Up-list, and Profitability in 2023: The Stage Has Been Set
SOUTH EASTON, MA / ACCESSWIRE / December 22, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and production services to the worldwide nutraceuticals, cosmetics, biotherapeutics, and food/beverage industries, among others, today offered guidance that the Company believes its Q4 2022 revenue will exceed quarterly revenue for any quarter over the past four years, and may achieve the highest quarterly revenue ever for the Company. PBI believes the foundations built and momentum achieved over the past several months will continue to accelerate, driven primarily by the recent commercial release of its revolutionary Ultra Shear Technology™ (UltraShear™ or UST™) platform. The Company further believes Q1 2023 revenue will greatly exceed Q4 2022's expected strong results, and that revenues in each successive quarter will surpass the prior quarter's level. Management expects the Company to reach breakeven/profitability by the end of 2023.
Future Outlook (The Stage Has Been Set): Q4 2022 & FY 2023.
Q4 2022: PBI expects to report highest quarterly revenue in past 4 years, likely highest ever.
FY 2023: each quarter expected to exceed prior quarter's revenue. UltraShear revenues expected to top $10M for 2023, beginning with over $1M in Q1 2023.
Agreements (UltraShear Toll Processing)
Company ending 2022 with 4 executed agreements; very close to final execution of six or more agreements.
Each agreement estimated to yield $1M or more in incremental annual revenue.
Expect data releases in Q1 2023 from key opinion leaders in academia and patient treatment/advocacy, supporting PBI's UltraShear Nano-CBD as among Best-in-Class in Bioavailability globally.
MA and CA market focus group studies underway to demonstrate expected superior speed of onset and absorption, supporting PBI's UltraShear Nano-THC as among Best-in-Class in Bioavailability globally.
Nutraceutical Supplements
Supply agreement with several multi-billion-dollar nutraceutical supplement leaders to be closed by mid-2023; strategic investment expected.
Immune Booster
Discussions underway with quality-leading, top-selling suppliers seeking assistance to nanosize oil-based active ingredients to be included in new, powerful Immune Booster product…including PBI's proven capabilities in curcumin, astaxanthin, and CBD.
PBI anticipates the Dr. Denese SkinScience partnership will strongly leverage data generated in 2022 studies of PBI's UltraShear processed Retinol and Lipid-Soluble Vitamin C, and from current on-going studies, to powerfully validate capabilities of UltraShear-enabled, next-generation, anti-aging serums from Dr. Denese, and will drive new achievements from her existing QVC marketing engine (with over $500M sales over 20 years), starting in Q1 2023.
How the Stage was Set: Review of FY 2022 Key Accomplishments
April: critical pivot in business focus from PCT Platform to Ultra Shear Technology Platform.
April: early access program for UltraShear nanoemulsion processing platform announced.
May: first agreement to make UltraShear-based Nano-CBD product – expected 2023 product revenues of $1M.
June: PBI partner Ohio State publishes/presents data to support UltraShear role in global $41B plant protein market.
July: second $1M+ agreement to process commercial UltraShear-based Nano-CBD products announced.
August: third agreement to process commercial Nano-CBD products. Projected FY 2023 revenues to exceed $3M.
August: PBI secures pivotal partnership with Dr. Denese SkinScience – QVC leader with $500M 20-year sales.
October: PBI and Dr. Denese announce UltraShear-enabled anti-aging and hair regrowth products for 2023 release.
December: Dr. Denese reports data on UltraShear Nano-Retinol greatly exceeds all performance expectations.
December: first commercial production of revolutionary UltraShear processed Nano-CBD product shipped and paid.
Mr. Richard T. Schumacher, President and CEO of PBI, commented: "Our development of UltraShear over the past 6 years presented a pivotal, game-changing nanoemulsions technology that we believe will restate the basis of competition for a myriad of products across multiple major industries. We have assembled a strong and differentiated IP position and unique engineering and scientific expertise to unleash this opportunity, for PBI and for clients worldwide. We made the critical decision in early 2022 to pivot our business focus and resources almost entirely onto accelerating the UltraShear platform, building commercial-stage UST processing equipment, creating pivotal technology demonstrations with select partners in multiple industries, and accelerating our path to commercial traction and a revenue growth inflection."
Mr. Schumacher concluded: "Our team has navigated a very challenging path to the achievement of this pivot point, and we are proud of what we have built. The stage has been set. Initial partners have been secured and our first commercial UltraShear product has been delivered and paid. Astonishing early demonstrations of UltraShear's unique differentiation of products continue to mount up, and more partners and early marketing results are gathering already for revenue acceleration in Q1 and throughout all of 2023. We are grateful daily for the patient support of our many long-term investors, and we are excited to have them at our side as PBI enters an exciting new era of revenue growth, profitability, and a planned uplist to a national exchange in 2023."
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the "BaroFold" technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
For more information about PBI and this press release, please click on the following website link:
Please visit us on Facebook, LinkedIn, and Twitter.
Press Contacts:
Richard T. Schumacher, President & CEO (508) 230-1828 (T)
John B. Hollister, Director of Sales and Marketing (805) 908-5719 (T)
Jeffrey N. Peterson, Board Chairman (650) 703-8557(T)
SOURCE: Pressure BioSciences, Inc.

View source version on accesswire.com:

Related Quotes
Michael Wilson, Morgan Stanley chief equity strategist, has been among the most prominent of the bearish prognosticators this past year, and while he still sees rough times ahead, he also offers some hope for the long term. At base, Wilson says the S&P 500 is likely to sink another 20% before hitting a bottom near 3,100 during 1Q23. The index slipped into a bear market in June of this year, when the Federal Reserve began its aggressive anti-inflationary interest rate hikes, and has been on a vol
This holiday season hasn’t exactly been filled with cheer for investors: Companies have been battling inflation and market volatility—and a recession seems to be looming ahead. Here’s what you need to know about trading hours ahead of Christmas. Investors who wish to make trades before Christmas Eve are in luck: The New York Stock Exchange and the Nasdaq Stock Market will be open on Friday.
In this video, I will cover Nvidia (NASDAQ: NVDA), AMD (NASDAQ: AMD), and Intel (NASDAQ: INTC), go over some company-specific news, and try and make sense as to why they were down 9%, 7%, and 5%, respectively, on Thursday, Dec.
2022 is almost over and although 2023 brings with it plenty of uncertainty, most investors will no doubt be happy that a tumultuous year for the stock market is finally coming to an end. The selling pressure has at times been so severe that it didn't really matter whether a stock has strong fundamentals or not, the reflex has been to throw the baby out with the bathwater. The upshot to the relentless selling is that now investors get a chance to load up on their favorite names at a big discount.
(Bloomberg) — Scott Minerd, the Guggenheim Partners chief investment officer who was regarded as one of the kings of the bond market during its four-decade bull run, has died. He was 63.Most Read from BloombergChina Is Likely Seeing 1 Million Covid Cases, 5,000 Deaths a DayDonald Trump’s Taxes Reveal Big Losses: What We Learned So Far, in ChartsBankman-Fried Released on $250 Million Bond in FTX CaseChina to Cut Quarantine for Overseas Travelers From Next MonthUS Stocks Snap Two Days of Gains; D
The bad news may continue for Tesla into 2023.
(Bloomberg) — Tesla Inc. is offering US consumers $7,500 to take delivery of its two highest-volume models before year-end, adding to indications the carmaker is struggling with demand.Most Read from BloombergChina Is Likely Seeing 1 Million Covid Cases, 5,000 Deaths a DayDonald Trump’s Taxes Reveal Big Losses: What We Learned So Far, in ChartsBankman-Fried Released on $250 Million Bond in FTX CaseChina to Cut Quarantine for Overseas Travelers From Next MonthUS Stocks Snap Two Days of Gains; Do
“They’re just a car company that has built too much capacity that they can’t sell," GLJ Research head Gordon Johnson said of Tesla this week.
Bonus: this trio provides diversification.
Shares of Applied Materials (NASDAQ: AMAT) fell as much as 9.4% in trading on Thursday as positive economic news and data out of China caused the market to fall. There were a number of factors impacting Applied Materials and semiconductor and industrial stocks more broadly. Data from China also indicated that imports of semiconductor equipment fell 40% in November from a year earlier due to U.S. export restrictions.
Yahoo Finance Live’s Brian Sozzi breaks down a Citi analyst’s bullish take on Apple.
Investors spent most of Thursday thinking easy come, easy go as major market benchmarks moved lower after sizable gains on Wednesday. Although the Dow Jones Industrial Average (DJINDICES: ^DJI), Nasdaq Composite (NASDAQINDEX: ^IXIC), and S&P 500 (SNPINDEX: ^GSPC) all finished well above their worst levels of the day, the volatility showed that levels of uncertainty about what 2023 will bring are extremely high. Both Cleveland-Cliffs (NYSE: CLF) and MillerKnoll (NASDAQ: MLKN) made their shareholders happy with some positive news about their respective businesses.
In this article, we will take a look at the 12 best get rich quick stocks to buy. If you want to see more stocks in this selection, go to the 5 Best Get Rich Quick Stocks To Buy. During times of high uncertainty, some experts recommend taking the short-term view instead of the long-term […]
Wood's flagship Ark Innovation ETF has dropped 66% year to date, and is down 80% from its February 2021 peak.
Despite all the pain from Elon Musk's Twitter distractions, Tesla ranks fourth on a list of the worst S&P 500 stocks of 2022 by market-value decline.
Management said its prices for specialized automotive steel would rise next year, and its costs would be lower.
Thursday is looking like a miserable day to own semiconductor stocks. Last night, after close of trading, computer memory-maker Micron (NASDAQ: MU) reported a fiscal Q1 2023 loss four times bigger than expected, and added that it also missed on sales. Instead of Wall Street's expected $0.01-per-share loss, Micron lost $0.04 per share in the quarter.
Mill Street Research Strategist Sam Burns joins Yahoo Finance Live to talk about Thursday's market activity, the outlook for the Fed in 2023, and more. 
Not long ago considered a trailblazing investing guru, sentiment has entirely shifted around Cathie Wood over the past year and a half. Her ARK Invest fund’s ARK Innovation ETF is loaded with growth-oriented pandemic-era winners but as anyone following the stock market’s trajectory will know, the tables have turned on stocks of that ilk. And the result is that the ARKK ETF is now down by a huge 65% in 2022. Does that mean Wood is ready to desert her strategy of backing innovative yet risky and o
With the New Year just a few days away, it’s time to start looking for the best portfolio choices going forward. This past year has been a mess for investors, and putting 2022’s bear market behind us will come as a relief – but finding solid choices for big gains will still require a high tolerance for risk. Fewer stock segments are more risky – or more potentially rewarding – than the penny stocks. Priced under $5 per share, these low-cost equities give investors a chance to double their money


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button